FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2051362023> ?p ?o ?g. }

• W2051362023 endingPage "414" @default.
• W2051362023 startingPage "405" @default.
• W2051362023 abstract "To evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profiles of CHF3381, a dual NMDA and MAO-A inhibitor, after multiple oral doses in healthy subjects.Forty-eight young males received CHF3381 at doses of 100 mg twice daily, 200 mg twice daily, 400 mg twice daily or placebo for 2 weeks according to a double-blind, randomized, parallel group design. Plasma and urine concentrations of the parent drug and of two major metabolites (CHF3567 and 2-aminoindane) were measured over time. MAO-A activity in plasma was estimated by measuring plasma concentrations of 3,4-dihydroxyphenylglycol. Sustained attention, memory and sedation were assessed throughout the study with standard psychometric tests.Most of the adverse events were mild in intensity, with dose regimens of 100 mg twice daily and 200 mg twice daily being indistinguishable from placebo. After 400 mg twice daily, the most frequent adverse events were mild dizziness, asthenia and insomnia. At steady-state, 400 mg twice daily slightly increased supine heart rate (+ 9 +/- 2 beats min(-1)) and diastolic blood pressure (+6 +/- 2 mmHg) compared with placebo. There were no dose-dependent or consistent effects of CHF3381 on attention, motor co-ordination or memory, but 400 mg twice daily significantly decreased alertness compared with placebo. Plasma concentrations of CHF3381 peaked at around 3 h and were dose-proportional. The elimination half-life of CHF3381 was estimated to be 4-6 h. At steady-state, significant CHF3381 plasma concentrations were detected at predose with a modest accumulation (1.3-1.5 times), showing that the drug given twice daily is active over the entire 24 h period. Plasma concentrations of CHF3567 and of 2-aminoindane were also proportional to the dose of CHF3381. CHF3381 dose-dependently inhibited MAO-A activity with peak effects at steady-state of 27 +/- 4%, 46 +/- 2% and 65 +/- 5% after 100 mg twice daily, 200 mg twice daily and 400 mg twice daily, respectively. There were no significant effects of CHF3381 on attention (rapid visual information processing), motor co-ordination (body sway) or memory (learning memory task) at any of the doses. At steady-state, there was a significant decrease in alertness (Bond & Lader visual analogue scale) in the 400 mg twice daily group compared with placebo.A twice daily regimen of CHF3381 appears to be adequate from a pharmacokinetic and pharmacodynamic perspective. Plasma concentrations reached with 400 mg twice daily exceeded those observed in animals receiving pharmacologically active doses in chronic pain models." @default.
• W2051362023 created "2016-06-24" @default.
• W2051362023 creator A5010091677 @default.
• W2051362023 creator A5026530055 @default.
• W2051362023 creator A5027574098 @default.
• W2051362023 creator A5028877971 @default.
• W2051362023 creator A5030878686 @default.
• W2051362023 creator A5078569425 @default.
• W2051362023 date "2005-02-09" @default.
• W2051362023 modified "2023-10-17" @default.
• W2051362023 title "Steady-state pharmacokinetics and pharmacodynamics of CHF3381, a novel antineuropathic pain agent, in healthy subjects" @default.
• W2051362023 cites W1575571855 @default.
• W2051362023 cites W1614280159 @default.
• W2051362023 cites W1972425876 @default.
• W2051362023 cites W1983565182 @default.
• W2051362023 cites W1984377108 @default.
• W2051362023 cites W1984832858 @default.
• W2051362023 cites W1985760250 @default.
• W2051362023 cites W1985980415 @default.
• W2051362023 cites W1990057142 @default.
• W2051362023 cites W1999483456 @default.
• W2051362023 cites W2000166916 @default.
• W2051362023 cites W2003066583 @default.
• W2051362023 cites W2004172882 @default.
• W2051362023 cites W2007478137 @default.
• W2051362023 cites W2035842873 @default.
• W2051362023 cites W2036166797 @default.
• W2051362023 cites W2036487197 @default.
• W2051362023 cites W2045724555 @default.
• W2051362023 cites W2055691970 @default.
• W2051362023 cites W2059053760 @default.
• W2051362023 cites W2064513638 @default.
• W2051362023 cites W2066869040 @default.
• W2051362023 cites W2073512962 @default.
• W2051362023 cites W2079882374 @default.
• W2051362023 cites W2088101006 @default.
• W2051362023 cites W2088180207 @default.
• W2051362023 cites W2092630898 @default.
• W2051362023 cites W2094233914 @default.
• W2051362023 cites W2096808564 @default.
• W2051362023 cites W2097162413 @default.
• W2051362023 cites W2103125895 @default.
• W2051362023 cites W2138799997 @default.
• W2051362023 cites W2155212844 @default.
• W2051362023 cites W2192609638 @default.
• W2051362023 cites W2431048141 @default.
• W2051362023 cites W3192541712 @default.
• W2051362023 cites W4244953414 @default.
• W2051362023 doi "https://doi.org/10.1111/j.1365-2125.2005.02338.x" @default.
• W2051362023 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1884805" @default.
• W2051362023 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15801935" @default.
• W2051362023 hasPublicationYear "2005" @default.
• W2051362023 type Work @default.
• W2051362023 sameAs 2051362023 @default.
• W2051362023 citedByCount "4" @default.
• W2051362023 crossrefType "journal-article" @default.
• W2051362023 hasAuthorship W2051362023A5010091677 @default.
• W2051362023 hasAuthorship W2051362023A5026530055 @default.
• W2051362023 hasAuthorship W2051362023A5027574098 @default.
• W2051362023 hasAuthorship W2051362023A5028877971 @default.
• W2051362023 hasAuthorship W2051362023A5030878686 @default.
• W2051362023 hasAuthorship W2051362023A5078569425 @default.
• W2051362023 hasBestOaLocation W20513620231 @default.
• W2051362023 hasConcept C111113717 @default.
• W2051362023 hasConcept C112705442 @default.
• W2051362023 hasConcept C126322002 @default.
• W2051362023 hasConcept C142724271 @default.
• W2051362023 hasConcept C197934379 @default.
• W2051362023 hasConcept C204787440 @default.
• W2051362023 hasConcept C27081682 @default.
• W2051362023 hasConcept C2776814716 @default.
• W2051362023 hasConcept C2777953023 @default.
• W2051362023 hasConcept C2778375690 @default.
• W2051362023 hasConcept C42219234 @default.
• W2051362023 hasConcept C71924100 @default.
• W2051362023 hasConcept C84393581 @default.
• W2051362023 hasConcept C98274493 @default.
• W2051362023 hasConceptScore W2051362023C111113717 @default.
• W2051362023 hasConceptScore W2051362023C112705442 @default.
• W2051362023 hasConceptScore W2051362023C126322002 @default.
• W2051362023 hasConceptScore W2051362023C142724271 @default.
• W2051362023 hasConceptScore W2051362023C197934379 @default.
• W2051362023 hasConceptScore W2051362023C204787440 @default.
• W2051362023 hasConceptScore W2051362023C27081682 @default.
• W2051362023 hasConceptScore W2051362023C2776814716 @default.
• W2051362023 hasConceptScore W2051362023C2777953023 @default.
• W2051362023 hasConceptScore W2051362023C2778375690 @default.
• W2051362023 hasConceptScore W2051362023C42219234 @default.
• W2051362023 hasConceptScore W2051362023C71924100 @default.
• W2051362023 hasConceptScore W2051362023C84393581 @default.
• W2051362023 hasConceptScore W2051362023C98274493 @default.
• W2051362023 hasIssue "4" @default.
• W2051362023 hasLocation W20513620231 @default.
• W2051362023 hasLocation W20513620232 @default.
• W2051362023 hasLocation W20513620233 @default.
• W2051362023 hasLocation W20513620234 @default.
• W2051362023 hasOpenAccess W2051362023 @default.
• W2051362023 hasPrimaryLocation W20513620231 @default.

• next